Wall Street Zen lowered shares of CVRx (NASDAQ:CVRX – Free Report) from a sell rating to a strong sell rating in a research report sent to investors on Sunday morning,Wall Street Zen reports.
Several other research analysts have also issued reports on CVRX. Craig Hallum lowered shares of CVRx from a “buy” rating to a “hold” rating and set a $4.00 price target for the company. in a research report on Friday, August 7th. Canaccord Genuity Group downgraded shares of CVRx from a “buy” rating to a “hold” rating and lowered their target price for the company from $5.00 to $2.00 in a research note on Friday, November 6th. Lake Street Capital cut their price objective on shares of CVRx from $3.50 to $1.50 and set a “hold” rating on the stock in a research report on Friday, November 6th. Piper Sandler downgraded shares of CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 target price for the company. in a research report on Friday, August 7th. Finally, William Blair cut shares of CVRx from an “outperform” rating to a “market perform” rating in a research note on Friday, November 6th. One investment analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $3.30.
Read Our Latest Stock Analysis on CVRX
CVRx Price Performance
CVRX opened at $0.61 on Friday. The business has a 50-day moving average of $1.85 and a 200-day moving average of $5.00. CVRx has a fifty-two week low of $0.60 and a fifty-two week high of $10.28. The company has a market capitalization of $17.30 million, a PE ratio of -0.30 and a beta of 0.81. The company has a debt-to-equity ratio of 4.24, a current ratio of 6.80 and a quick ratio of 5.71.
CVRx (NASDAQ:CVRX – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.02). CVRx had a negative return on equity of 208.45% and a negative net margin of 88.28%. The business had revenue of $13.83 million during the quarter, compared to the consensus estimate of $13.93 million. Equities research analysts forecast that CVRx will post -2.04 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. Johnson & Johnson acquired a new position in CVRx in the 2nd quarter valued at $20,687,786. BlackRock Inc. acquired a new stake in shares of CVRx during the second quarter worth $6,402,000. Royal Bank of Canada lifted its holdings in shares of CVRx by 6,559.3% during the first quarter. Royal Bank of Canada now owns 706,950 shares of the company’s stock worth $6,688,000 after buying an additional 696,334 shares in the last quarter. FourWorld Capital Management LLC boosted its position in shares of CVRx by 28.9% in the first quarter. FourWorld Capital Management LLC now owns 231,996 shares of the company’s stock valued at $2,195,000 after acquiring an additional 51,996 shares during the period. Finally, First Eagle Investment Management LLC bought a new stake in shares of CVRx in the third quarter valued at about $386,000. Institutional investors and hedge funds own 75.27% of the company’s stock.
Key Stories Impacting CVRx
These are some of the CVRX stories that stood out recently:
- Negative Sentiment: Investors allege CVRx misled shareholders during July 25, 2023–August 6, 2026, including about alleged conduct that could expose the company to liability under the False Claims Act and Anti-Kickback Statute. The complaints cite a DOJ Civil Investigative Demand, sharp revenue-guidance reductions, disruption to the commercial sales force, and the departure of the chief revenue officer. These remain allegations, not proven findings; continued litigation could bring costs and uncertainty. Securities fraud lawsuit report Hagens Berman class-action notice
- Neutral Sentiment: Law firms are publicizing the case and urging eligible investors to seek appointment as lead plaintiff by January 8, 2027. These repeated notices largely concern the same lawsuit rather than separate new cases or company operating updates. Lead plaintiff deadline notice
About CVRx
CVRx, Inc. is a medical technology company that develops and commercializes implantable neuromodulation devices for cardiovascular conditions. Its technology is designed to influence the autonomic nervous system, which helps regulate functions such as heart rate and blood pressure. The company’s primary product is Barostim, an implantable system that delivers electrical signals to baroreceptors in the carotid artery. In the United States, Barostim is approved to improve symptoms for certain patients with heart failure who remain symptomatic despite medical therapy.
Featured Stories
- Five stocks we like better than CVRx
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.
